ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Current capacity 1000 tests per day

<< Previous

Bullboard Posts

Next >>

Comment by DavidKingCanadaon Oct 03, 2021 8:51am

149 Views

Post# 33958476

RE:RE:RE:RE:RE:RE:RE:RE:Current capacity 1000 tests per day

The whole deal with BCNI seems a bit shady to me. $3000.00 and the they own 50% of Potential Net Income after all Expenses. Covid-19 is Over. There were many other Companies that had a working and were selling their Tests during Covid. They have now stopped. Does it make any sense for PMN to continue? Maybe they should take there $3000.00 Loss and be honest with Shareholders.

For those to sensitive to this or have there life savings invested in PMN, you might want to cash out once it goes above 0.20 otherwise stop crying about it especially if you have "Million" Shares plus witch we highly doubt.

<< Previous

Bullboard Posts

Next >>

Canadian government to fund Electric Royalties portfolio property